Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Medical cannabis use in Canadians with multiple sclerosis

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

DOI

  1. The Effects of Exo- and Endocannabinoids in Multiple Sclerosis

    Publikation: Bog/antologi/afhandling/rapportPh.d.-afhandling

Vis graf over relationer

BACKGROUND: The extent of medical cannabis use by people with multiple sclerosis (MS) in Canada has not been evaluated for more than a decade since recreational cannabis was legalized. Legalization provided an avenue for those to whom legal cannabis was previously inaccessible to access it as an alternative therapy. Our objective was to evaluate the prevalence of medical cannabis use by Canadians with MS, the reasons it is used, adverse effects, as well as the context surrounding how it is obtained and where users learned about it.

METHODS: An anonymous questionnaire was distributed to prospective participants through various channels. The questionnaire included questions about participant characteristics and quality of life, their MS, and their medical cannabis use. It also employed two validated patient-reported outcome measures, the PDDS and the MSQOL-54.

RESULTS: Completed questionnaires were submitted by 344 individuals. Among respondents, 215/344 (64.5%) reported having used medical cannabis at least once, and 180 (52.3%) reported still currently using it. Based on disease and quality of life data, we found that respondents with more severe or progressive forms of MS were more likely to have tried medical cannabis. Medical cannabis was used most by current and former users to treat sleep problems (84.2%), pain (80.0%), and spasticity (68.4%), while the most reported adverse effects were drowsiness (57.2%), feeling quiet/subdued (48.8%), and difficulty concentrating (28.4%). Most current and former users obtained their cannabis from a legal, reliable source (76.1%) and many (74%) learned about medical cannabis from someone other than a healthcare provider.

CONCLUSIONS: This study showed that nearly two-thirds of survey respondents, comprised of Canadians living with MS, have tried medical cannabis at least once and that those with a greater disease burden were more likely to have tried it. Users reported that cannabis is moderately to highly effective in treating several symptoms and that adverse effects are not generally severe, nor are they the main factor driving medical cannabis cessation. Our results support the need for more research examining medical cannabis use in MS and for evidence-based resources to be publicly available for those exploring it as a potential therapy.

OriginalsprogEngelsk
Artikelnummer103638
TidsskriftMultiple Sclerosis and Related Disorders
Vol/bind59
Sider (fra-til)103638
ISSN2211-0348
DOI
StatusUdgivet - mar. 2022

Bibliografisk note

Copyright © 2022. Published by Elsevier B.V.

ID: 79501977